Clinical trials: Interstitial Fibrosis
Idiopathic Pulmonary Fibrosis
Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient…
- Trial name
- NCT05870956
- Testing
- Nintedanib
- Where
- United States
- Volunteers
- 1,798 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Genentech Xenon MRI Idiopathic Pulmonary Fibrosis
The purpose of this study is being done to determine whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic…
- Trial name
- NCT04071769
- Testing
- Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Duke University
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or…
- Conditions
- Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT00105183
- Testing
- EZ-2053, EZ-2053 5mg/kg
- Where
- 19 sites in United States, Australia and 2 more
- Volunteers
- 223 people
- Sponsor
- Neovii Biotech
Idiopathic Pulmonary Fibrosis
Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging
GSK3008348 is being developed as a treatment for IPF. A first-time-in-human study showed that single nebulized doses of 1-3000 micrograms (mcg) GSK3008348 in healthy volunteers were well tolerated, with pharmacokinetic (PK)…
- Trial name
- NCT03069989
- Testing
- GSK3008348, [18F]-FBA-A20FMDV2
- Where
- 3 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory patients with idiopathic pulmonary fibrosis.
- Trial name
- GKT137831 (NCT03865927)
- Testing
- GKT137831
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Alabama at Birmingham
Idiopathic Pulmonary Fibrosis
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
This study will test the effectiveness of warfarin in patients with IPF. Approximately 256 patients will be randomized 1:1 to either warfarin or placebo.
- Trial name
- ACE-IPF (NCT00957242)
- Testing
- warfarin
- Where
- 22 sites in United States
- Volunteers
- 145 people
- Sponsor
- Duke University
Idiopathic Pulmonary Fibrosis
Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This clinical study will evaluate the safety and tolerability of combination treatment of nintedanib and pirfenidone in participants with IPF.
- Trial name
- NCT02598193
- Testing
- Nintedanib, Pirfenidone
- Where
- 38 sites in United States, Canada and 6 more
- Volunteers
- 89 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
HZNP-HZN-825-303 (HARBOR) comprises of 2 parts. Part 1 (Core Phase) is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety and tolerability of HZN-825 in participants…
- Trial name
- NCT05032066
- Testing
- HZN-825
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 153 people
- Sponsor
- Amgen
Idiopathic Pulmonary Fibrosis
Investigating Idiopathic Pulmonary Fibrosis in Greece
To gain further insight on the characteristics, management, disease progression and the outcomes of patients with IPF, as diagnosed and treated under real-world, clinical practice conditions in Greece.
- Trial name
- INDULGEIPF (NCT03074149)
- Where
- 7 sites in Greece
- Volunteers
- 301 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA2 (NCT03733444)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Argentina and 13 more
- Volunteers
- 781 people
- Sponsor
- Lakefront Biotherapeutics NV
Pulmonary Fibrosis
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid…
- Trial name
- NCT01335477
- Testing
- BIBF 1120
- Where
- 108 sites in United States, Canada and 15 more
- Volunteers
- 551 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old.
- Trial name
- NCT05065190
- Testing
- Nintedanib
- Where
- 16 sites in China
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
D2212C00002 J-Phase II Study
The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT02036580
- Testing
- tralokinumab cohort 1, tralokinumab cohort 2
- Where
- 5 sites in Japan
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Pulmonary Fibrosis
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
The general purpose of this trial is to investigate the efficacy and safety of 4 dose strategies of BIBF 1120 treatment for 12 months, compared to placebo in patients with idiopathic pulmonary fibrosis.
- Trial name
- NCT00514683
- Testing
- low dose BIBF1120 once daily, low dose BIBF 1120 twice daily, intermediate dose BIBF 1120 twice daily
- Where
- 92 sites in Argentina, Australia and 23 more
- Volunteers
- 432 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
The primary objective of this study is to establish the feasibility and safety of infusions of placental Mesenchymal Stem Cells (MSC) from related or unrelated HLA identical or HLA mismatched donors in the treatment of Idiopathic…
- Trial name
- MSC in IPF (NCT01385644)
- Testing
- Placental MSC
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- The Prince Charles Hospital
Idiopathic Pulmonary Fibrosis
Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause that results in scarring of the lungs. Cough is reported by 85% of patients with IPF and can be a distressing symptom with significant physical, social and…
- Trial name
- PAciFy Cough (NCT04429516)
- Testing
- Morphine Sulfate
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis…
- Trial name
- STARSCAPE (NCT04552899)
- Testing
- PRM-151 (Zinpentraxin Alfa)
- Where
- 360 sites in United States, Argentina and 33 more
- Volunteers
- 665 people
- Sponsor
- Hoffmann-La Roche
Covid19, Post-acute COVID-19 Respiratory Disease
LYT-100 in Post-acute COVID-19 Respiratory Disease
This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory…
- Trial name
- NCT04652518
- Testing
- LYT-100
- Where
- 31 sites in United States, Argentina and 6 more
- Volunteers
- 185 people
- Sponsor
- PureTech
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease
Interstitial lung disease (ILD) is the result of over 200 etiological pathways arising from several different insults to the lung parenchyma: inhaled substances, drug side effects, connective tissue disease, infection, and…
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Interstitial Pneumonitis, Desquamative Interstitial Pneumonia
- Trial name
- NCT02019641
- Testing
- Aerobic Exercise Training (AET), Education
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Institutes of Health Clinical Center (CC)